Mylan makes major pharma acquisition in India

NYSE-listed Mylan Laboratories to acquire 71.5% of IndiaÆs Matrix Laboratories for a maximum price of $736 million in deal in which private equity investors in Matrix Laboratories will take a stake in acquirer, Mylan.

NYSE listed Mylan Laboratories Mylan announced on August 28 that it will acquire 71.5% of IndiaÆs Matrix Laboratories for a maximum price of $736 million. The transaction has been structured in a way that part of the gains realised by the private equity firms on their investment in Matrix Laboratories will be reinvested in acquirer, Mylan. The deal values Matrix at $1.03 billion and represents a 22 times earnings multiple. The transaction is one of the largest to date for...

To continue reading, please login or register for free

Click for more on: mylan | matrix | temasek | newbridge

Print Edition

FinanceAsia Print Edition

CONFERENCES

  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...